Pricing Log in Create free account

MapLight Therapeutics, Inc. (MPLT) vs ProKidney Corp. (PROK)

MapLight Therapeutics, Inc. and ProKidney Corp. are both Biotechnology companies. MapLight Therapeutics, Inc. and ProKidney Corp. are of similar size ($445.7M and $439.9M). MapLight Therapeutics, Inc. has the higher net margin (0.00% vs −10,288.4%) and the lower return on invested capital (−348.4% vs 0.00%). Across the 11 metrics below, MapLight Therapeutics, Inc. leads on 6 and ProKidney Corp. on 5.

Valuation

Metric MPLT PROK Biotechnology median
P/E n/m n/m 8.50
P/S n/m 303.33 9.71
P/B 1.00 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 81.78 9.21
Earnings yield (549.48%) (41.35%) (33.15%)
Free cash flow yield (50.06%) (57.04%) (25.50%)

Profitability

Metric MPLT PROK Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (21,664.55%) 0.00%
Net margin 0.00% (10,288.39%) 0.00%
Free cash flow margin 0.00% (17,300.61%) 0.00%
Return on equity (297.18%) 8.92% (56.36%)
Return on assets (124.79%) (27.10%) (48.04%)
Return on invested capital (348.44%) 0.00% 0.00%

Growth

Metric MPLT PROK Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 82.39% 16.13% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MPLT PROK Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.52 8.36 4.72
Net debt to EBITDA 1.79 1.70 0.96

Dividend

Metric MPLT PROK Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MPLT PROK Biotechnology median
Market cap 445.72m 439.88m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack